Consequently, a high proportion of TILs in TNBC and HER2+ tumors will predict a better response to PD-1 inhibitors [139], which would confirm the therapeutic potential of immune checkpoint blockade in BC patients [140]. The gene discussed is ERBB2; the disease is breast cancer.